BGLC vs AEYE vs ALKT vs QDEL vs BIO

For growth investors, Alkami Technology, Inc.

(ALKT) is the stronger pick with 32. 9% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 1x trailing P/E (27. 4x forward), making it the more compelling value choice. Analysts rate Alkami Technology, Inc. (ALKT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, QuidelOrtho Corporation is actually cheaper at 6.

0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alkami Technology, Inc.

(ALKT) delivered a total return of -53. 8%, compared to -98. 6% for BioNexus Gene Lab Corp. (BGLC). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus BGLC's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 91β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 150% more volatile than BIO relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alkami Technology, Inc.

(ALKT) is pulling ahead at 32. 9% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -12. 2% for Alkami Technology, Inc.. Over a 3-year CAGR, ALKT leads at 29. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -41. 5% for QuidelOrtho Corporation — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIO leads at 10. 5% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

0x forward P/E versus 27. 4x for Bio-Rad Laboratories, Inc. — 21. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIO: 22. 9% to $312. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91)). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIO: +79. 3%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BGLC (Healthcare) and AEYE (Technology) and ALKT (Technology) and QDEL (Healthcare) and BIO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BGLC is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; QDEL is a small-cap quality compounder stock; BIO is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.